2. Signaling Pathways
  3. Immunology/Inflammation
  4. MHC

MHC

Major Histocompatibility Complex; MHC

MHC is a group of genes encoding proteins which are transferred to the cell surfaces to present the intracellular or extracellular, self or non-self antigens to the cells of the immune system, thereby helping T cells in differentiating self from non-self proteins, and initiating adaptive immune responses. MHC can be divided into 3 subtypes, MHC I, MHC II and MHC III, in which MHC I presents endogenous antigens (such as antigens produced by virus-infected cells or tumor cells) to activate cytotoxic T cells (CD8+ T cells); MHC II presents exogenous antigens (such as bacteria or parasites) to activate helper T cells (CD4+ T cells); MHC III does not directly participate in antigen presentation, but involves in immune regulation, inflammatory response and cell signaling. MHC is crucial for stem cell transplant (SCT), and could lead to graft-versus-host disease (GVHD)[1][2].

MHC Isoform Specific Products:

MHC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P5898
    Z-Val-Val-Nle-diazomethylketone
    		Inhibitor
    Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the MHCII molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research.
    Z-Val-Val-Nle-diazomethylketone
  • HY-P991142
    Isuventatug
    		Ligand
    Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy.
    Isuventatug
  • HY-177091
    AS2795440
    		Inhibitor
    AS2795440 is a PIKfyve inhibitor. AS2795440 selectively inhibits proinflammatory cytokine such as IL-12p40 and IL-6 production and B cell activation without affecting Ca2+ signaling. AS2795440 significantly reduces joint inflammation and bone loss in adjuvant-induced arthritis (AIA) mice model. AS2795440 can be used for inflammatory and autoimmune diseases like rheumatoid arthritis, psoriasis and inflammatory bowel disease research.
    AS2795440
  • HY-P11127
    MBP (111-129)
    MBP (111-129) is a polypeptide that constitutes an immunodominant epitope cluster restricted by HLA-DRB1*0401. MBP (111-129) is an antagonist for the clone HD4-1C2 TCR and an agonist for clone MS2-3C8 TCR. MBP (111-129) can be used for on multiple sclerosis and T cell biology.
    MBP (111-129)
  • HY-P11340
    VMAPRTLFL
    		Ligand
    VMAPRTLFL is a 9-mer peptide derived from the signal peptide of HLA-G and can serve as a peptide ligand for HLA-E. VMAPRTLFL plays a crucial role in regulating the functions of adaptive natural killer (NK) cells. Specifically, VMAPRTLFL enriches FcεRγ- adaptive NK cells, upregulates the expression of CD25, and enhances their proliferative activity, antibody-dependent cellular cytotoxicity (ADCC), and IFN-γ release. VMAPRTLFL can be used in research related to human cytomegalovirus (HCMV) infection, transplant rejection, and pregnancy immunity.
    VMAPRTLFL
  • HY-106156
    Allotrap 07
    Allotrap 07 is a synthetic peptide composed of residues 75-84 of HLA-B7, a class I MHC molecule. Allotrap 07 combined with Cyclosporin A (HY-B0579) induces donor-specific tolerance in rat cardiac allografts, significantly prolonging graft survival.
    Allotrap 07
  • HY-P5745A
    TYVPANASL TFA
    TYVPANASL TFA is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL TFA can be used to prepare J-LEAPS vaccine.
    TYVPANASL TFA
  • HY-171883
    BI-5756
    		Modulator
    BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatory T cells while maintaining T cell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases.
    BI-5756
  • HY-P990188
    Anti-Mouse MHC class II (I-A) Antibody (Y-3P)
    Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC class II. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) reacts with mouse MHC Class II haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly with I-Ak. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) blocks MHC class II and inhibits expansion of regulate T cells. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) can be used for the immunology research.
    Anti-Mouse MHC class II (I-A) Antibody (Y-3P)
  • HY-P1745
    InsB (9-23)
    InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7. InsB (9-23) can be used to treat a number of autoimmune related diseases like Type 1 diabetes.
    InsB (9-23)
  • HY-160151
    TP1L
    		Activator
    TP1L is a potent and selective T-cell protein tyrosine phosphatase (TC-PTP) PROTAC degrader, with a DC50 value of 35.8 nM. TP1L elevates the phosphorylation level of TC-PTP substrates including pSTAT1 and pJAK1. TP1L selectively enhances IFN-γ signaling and increases MHC-I expression. TP1L activates TCR signaling through increases phosphorylation of LCK. TP1L enhances CAR-T cell mediated tumor killing efficacy through activation of the CAR-T cells. TP1L can be used for the study of cancer. (Pink: TC-PTP ligand: (HY-138964), Blue: E3 ligase CRBN Ligand (HY-A0003), Black: Linker: (HY-140002)).
    TP1L
  • HY-P990161
    Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11)
    		Inhibitor
    Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an anti-mouse TCR Vγ1.1/Cr4 IgG monoclonal antibody. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can deplete Vγ1 γδ T cells. Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) can be used for research on cancer and inflammation conditions such as mastitis and colon cancer.
    Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11)
  • HY-P990160
    Anti-Rat TCR alpha/beta Antibody (R73)
    		Inhibitor
    Anti-Rat TCR alpha/beta Antibody (R73) is an anti-mouse TCR alpha/beta IgG1 monoclonal antibody. Anti-Rat TCR alpha/beta Antibody (R73) suppresses immune response by depleting α/β+ T cells. Anti-Rat TCR alpha/beta Antibody (R73) can inhibit the expression of pro-inflammatory cytokines. Anti-Rat TCR alpha/beta Antibody (R73) can extend graft survival time by reducing infiltration of T cells and neutrophils. Anti-Rat TCR alpha/beta Antibody (R73) can be used for researches on inflammation, metabolic conditions and xenotransplantation such as arthritis, acute inflammatory peripheral neuropathy and diabetes.
    Anti-Rat TCR alpha/beta Antibody (R73)
  • HY-P11090
    TpD
    TpD is a chimeric T-helper epitope. TpD has a special site that cathepsin can cut. Immunization with TpD produces a strong antibody response. TpD promotes long-term CD4 immune responses in animals and humans. TpD binds well to many human MHC class II types, mainly HLA-DRB1. It also binds some other HLA alleles like DRB3, DRB4, DRB5, DP, and DQ. TpD can be used to improve the immune response of peptide vaccines.
    TpD
  • HY-P991247
    Anti-HLA-A2 (Hu8F4)
    		Inhibitor
    Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-HLA-A2 (Hu8F4)
  • HY-P10382
    M133 peptide
    M133 peptide is a coronavirus-specific CD4 T cell epitope. M133 peptide is immunodominant in mice infected with the neurotropic coronavirus (the JHM strain of mouse hepatitis virus). M133 peptide forms a complex with MHC II molecules, which is recognized by specific TCRs, thereby activating CD4 T cells.
    M133 peptide
  • HY-P990159
    Anti-Mouse TCRβ Antibody (HB218)
    		Inhibitor
    Anti-Mouse TCRβ Antibody (HB218) is an anti-mouse TCRβ IgG2b monoclonal antibody. Anti-Mouse TCRβ Antibody (HB218) can deplete TCRβ+ T cells. Anti-Mouse TCRβ Antibody (HB218) can be used for research on inflammation conditions and cancer such as spontaneous dermatitis and squamous cell carcinoma (SCC).
    Anti-Mouse TCRβ Antibody (HB218)
  • HY-105488
    MDL 201112
    MDL 201112 is a carbocyclic nucleoside. MDL 201112 can decrease TNF-α production and inhibit MHC class II Ia+ antigen expression. MDL 201112 can be used for the research of inflammation and immunology.
    MDL 201112
  • HY-P11089
    TP53 neoepitope
    		Substrate
    TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8+ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .
    TP53 neoepitope
  • HY-P991590
    1D09C3
    1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL).
    1D09C3
MHC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.